Equities Analysts Offer Predictions for NAGE Q3 Earnings

Key Points

• Roth Capital has revised down its Q3 2025 earnings estimate for Niagen Bioscience to $0.00 per share from $0.01, while maintaining a "Buy" rating and a price target of $23.00.
• Niagen Bioscience reported earnings of $0.04 per share for Q2, exceeding the consensus estimate, with a revenue of $31.12 million, surpassing expectations of $28.55 million.
• Institutional ownership in Niagen Bioscience stands at 15.41%, with several investors recently increasing their stakes in the company.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Analysts at Roth Capital lowered their Q3 2025 EPS estimates for shares of Niagen Bioscience in a research note issued on Thursday, August 7th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings per share of $0.00 for the quarter, down from their previous estimate of $0.01. Roth Capital has a "Buy" rating and a $23.00 price objective on the stock. Roth Capital also issued estimates for Niagen Bioscience's FY2025 earnings at $0.08 EPS, FY2026 earnings at $0.13 EPS, Q2 2027 earnings at $0.07 EPS and FY2027 earnings at $0.26 EPS.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The company had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%.

A number of other research firms also recently issued reports on NAGE. Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 2nd. Canaccord Genuity Group lifted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Finally, HC Wainwright lifted their price objective on shares of Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Monday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Niagen Bioscience presently has an average rating of "Buy" and a consensus price target of $13.42.

Niagen Bioscience Price Performance

Shares of NASDAQ:NAGE traded up $0.48 during mid-day trading on Friday, hitting $10.30. The company had a trading volume of 629,885 shares, compared to its average volume of 948,966. The firm has a fifty day moving average price of $11.73 and a 200 day moving average price of $8.31. Niagen Bioscience has a one year low of $2.81 and a one year high of $14.69. The company has a market capitalization of $821.43 million, a PE ratio of 49.05 and a beta of 2.12.

Hedge Funds Weigh In On Niagen Bioscience

Several large investors have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. raised its position in Niagen Bioscience by 1,785.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock worth $5,365,000 after buying an additional 957,665 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Niagen Bioscience during the 4th quarter valued at approximately $1,647,000. Renaissance Technologies LLC boosted its stake in Niagen Bioscience by 68.0% during the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock valued at $3,781,000 after buying an additional 288,588 shares during the last quarter. Millennium Management LLC bought a new position in Niagen Bioscience during the fourth quarter valued at approximately $1,199,000. Finally, Ameriprise Financial Inc. boosted its stake in Niagen Bioscience by 212.5% during the fourth quarter. Ameriprise Financial Inc. now owns 329,988 shares of the company's stock valued at $1,751,000 after buying an additional 224,399 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company's stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.